Bio-Path Holdings (BPTH)

• Market cap: $3.53M
• 1 day: 0.74%
• 5 days: -13.68%
• 1 month: 18.16%
• 3 months: -23.36%
• 6 months: -57.51%
• Year to date: -28.70%
• 1 year: -90.56%
• 5 years: -99.46%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Employees: 10

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

0% more funds holding

Funds holding: 13 [Q2] → 13 (+0) [Q3]

4.54% less ownership

Funds ownership: 6.86% [Q2] → 2.32% (-4.54%) [Q3]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

85% less capital invested

Capital invested by funds: $285K [Q2] → $42.5K (-$243K) [Q3]